CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an update on the status of its development programs. KalVista now expects to complete enrollment for the KVD900 Phase 2 clinical trial before year-end 2019 and to provide data in 2020. The Phase 2 clinical trial of KVD001 in DME is still exp